Atai Life Sciences rises after $130 mln equity offering

AtaiBeckley

17/10/2025 14:50

**  U.S.-listed shares of Atai Life Sciences ATAI.O up 7% at $5.86 early Fri after co raises equity

    ** Netherlands-based biopharma late Thurs announced pricing ~23.7 mln shares at $5.48 for $130 mln gross proceeds

    ** Offering price matches ATAI shares last close. They fell about 8% on Thurs

    ** After the bell Thurs, Atai and Oxford, U.K.-based Beckley Psytech said U.S. FDA granted their experimental depression drug, BPL-003, "breakthrough therapy" designation

    ** A breakthrough therapy tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need

    ** Atai
    plans to use net offering proceeds to advance clinical development of drug candidates/programs, among other purposes

    ** Co has ~214.3 mln shares outstanding

    ** Jefferies lead bookrunner for offering, joined by Berenberg as a passive bookrunner

    ** In Jun, Atai announced $390 mln merger with Beckley Psytech to create a combined psychedelic mental health therapy firm

    ** With the move on Fri, U.S.-listed ATAI shares have quadrupled over the past six months

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))